Doctors apparently opt out of suggesting generic versions of brand name drugs to their patients.
And the cost of this "oversight"? Probably in the tens of billions a year.
At least that's what researchers from Ohio State and (arch football rival) University of Michigan found when they studied the records of more than 100,000 patient from the 2010 to 2012 period.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.